Avances en el enfrentamiento diagnóstico y terapéutico de la acromegalia

Acromegaly is a rare disorder, primarily caused by benign growth hormone-secreting tumors of the pituitary gland, leading to multisystemic complications and increased morbidity and mortality. This review aims to show the most updated advances in its management, which should be individualized and conducted by specialized multidisciplinary teams with expertise in pituitary disorders. Surgery, when performed by experienced surgeons, remains the first-line treatment in most cases. For patients with persistent disease, alternative therapeutic options include radiation, repeat surgery, and pharmacological agents targeting different molecular pathways, such as first and second-generation somatostatin analogs, dopamine agonists, and growth hormone receptor antagonists, among others. A multimodal treatment approach, combining multiple therapeutic strategies, has been shown to achieve high remission rates. Treatment selection should be tailored based on clinical, biochemical, radiological, and histological parameters to optimize outcomes, minimize long-term complications, and ultimately improve patients’ quality of life.